# Neoadjuvent Dose-dense Gemcitabine and Cisplatin In Muscle Invasive Bladder Cancer

> **NCT07184021** · PHASE2 · NOT_YET_RECRUITING · sponsor: **Assiut University** · enrollment: 30 (estimated)

## Conditions studied

- Urinary Bladder Cancer

## Interventions

- **DRUG:** Gemcitabine and Cisplatin (DD GC)

## Key facts

- **NCT ID:** NCT07184021
- **Lead sponsor:** Assiut University
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** NOT_YET_RECRUITING
- **Start date:** 2025-09
- **Primary completion:** 2027-09
- **Final completion:** 2027-09
- **Target enrollment:** 30 (ESTIMATED)
- **Last updated:** 2025-09-19


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT07184021

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT07184021, "Neoadjuvent Dose-dense Gemcitabine and Cisplatin In Muscle Invasive Bladder Cancer". Retrieved via AI Analytics 2026-07-07 from https://api.ai-analytics.org/clinical/NCT07184021. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*